GLPG

Galapagos NV ADR

Oct 15 • 10:11AM ET

34.10

+0.60 1.78 %

Healthcare • Biotechnology • Belgium • NASD

Peers: GILD VRTX REGN AMGN BIIB INCY NBIX RARE EXEL BMRN

| Held by: IBB SBIO AVDE APIE AVDS AVSD BIB IBBQ

Index	-	P/E	-	EPS (ttm)	-4.70	Insider Own	25.35%	Shs Outstand	65.90M	Perf Week	-1.17%
Market Cap	2.25B	Forward P/E	-	EPS next Y	-1.64	Insider Trans	0.00%	Shs Float	49.19M	Perf Month	6.48%
Enterprise Value	-1.40B	PEG	-	EPS next Q	-0.35	Inst Own	23.56%	Short Float	3.37%	Perf Quarter	11.20%
Income	-309.81M	P/S	7.51	EPS this Y	-474.74%	Inst Trans	-3.29%	Short Ratio	5.85	Perf Half Y	42.78%
Sales	299.25M	P/B	0.72	EPS next Y	62.51%	ROA	-6.92%	Short Interest	1.66M	Perf YTD	23.98%
Book/sh	47.10	P/C	0.61	EPS next 5Y	-	ROE	-10.10%	52W High	37.78 -9.75%	Perf Year	14.37%
Cash/sh	55.46	P/FCF	-	EPS past 3/5Y	- -16.02%	ROIC	-9.96%	52W Low	22.36 52.48%	Perf 3Y	-17.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.57% -20.42%	Gross Margin	87.77%	Volatility	2.00% 2.32%	Perf 5Y	-75.86%
Dividend TTM	-	EV/Sales	-4.67	EPS Y/Y TTM	-102.48%	Oper. Margin	-133.90%	ATR (14)	0.88	Perf 10Y	-25.20%
Dividend Ex-Date	-	Quick Ratio	7.99	Sales Y/Y TTM	-	Profit Margin	-103.53%	RSI (14)	51.47	Recom	3.46
Dividend Gr. 3/5Y	- -	Current Ratio	8.08	EPS Q/Q	-1339.99%	SMA20	-0.64%	Beta	0.24	Target Price	31.96
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-11.66%	SMA50	3.20%	Rel Volume	0.25	Prev Close	33.50
Employees	704	LT Debt/Eq	0.00	Earnings	Jul 23 AMC	SMA200	19.82%	Avg Volume	283.50K	Price	34.10
IPO	Jul 07, 2008	Option/Short	Yes / Yes	EPS/Sales Surpr.	-708.54% -2.02%	Trades		Volume	10,729	Change	1.78%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-25	Downgrade	Deutsche Bank	Hold → Sell
Feb-14-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$31 → $22
Nov-20-24	Downgrade	Kepler	Hold → Reduce
Sep-09-24	Initiated	Leerink Partners	Market Perform	$24
Aug-02-24	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-28-24	Downgrade	BofA Securities	Neutral → Underperform	$41 → $31
Mar-07-24	Resumed	Morgan Stanley	Equal-Weight	$38
Aug-24-23	Downgrade	Citigroup	Buy → Neutral
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-23	Upgrade	Jefferies	Underperform → Hold	$49 → $47.20
Nov-07-22	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$80 → $61
Jan-27-22	Upgrade	Citigroup	Neutral → Buy
Aug-19-21	Downgrade	Barclays	Overweight → Equal Weight
Aug-06-21	Downgrade	Deutsche Bank	Buy → Hold
Apr-20-21	Initiated	Deutsche Bank	Buy
Apr-14-21	Upgrade	Barclays	Equal Weight → Overweight
Feb-23-21	Upgrade	BofA Securities	Underperform → Neutral	$93 → $94
Feb-19-21	Upgrade	Raymond James	Mkt Perform → Outperform
Feb-11-21	Downgrade	Citigroup	Buy → Neutral

Show Previous Ratings

Sep-11-25 11:18AM	Galapagos NV (GLPG)' CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial (Insider Monkey)
Aug-07-25 04:01PM	Galapagos Creates New Subscription Right Plan (GlobeNewswire)
Aug-06-25 01:30AM	Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (GlobeNewswire)
Jul-23-25 04:03PM	Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation (GlobeNewswire) -7.33%
04:02PM	Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors (GlobeNewswire)
04:01PM	Loading…
04:01PM	Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update (GlobeNewswire)
Jun-23-25 01:30AM	Galapagos Appoints Aaron Cox as Chief Financial Officer (GlobeNewswire)
Jun-18-25 04:01PM	Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101 (GlobeNewswire)
Jun-12-25 04:01PM	Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL (GlobeNewswire)
May-27-25 04:33PM	Galapagos Creates New Subscription Right Plan (GlobeNewswire)
May-14-25 04:01PM	Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 (GlobeNewswire)
May-13-25 01:36AM	Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes (GlobeNewswire) +7.06%
Apr-25-25 06:16PM	Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101 (Seeking Alpha)
Apr-24-25 11:34AM	Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript (Seeking Alpha)
Apr-23-25 04:01PM	Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts (GlobeNewswire)
04:10PM	Loading…
Apr-21-25 04:10PM	Galapagos Announces Executive Leadership Updates (GlobeNewswire)
Apr-15-25 01:30AM	Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 (GlobeNewswire)
Apr-11-25 03:05PM	Is Galapagos (GLPG) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-27-25 04:01PM	Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting (GlobeNewswire)
Feb-24-25 04:01PM	Galapagos to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-17-25 04:01PM	Galapagos receives transparency notification and 13D filing from Tang Capital (GlobeNewswire)
Feb-12-25 04:01PM	Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update (GlobeNewswire) +7.21%
Jan-08-25 01:30AM	Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities (GlobeNewswire)
Jan-07-25 04:01PM	Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-24 12:30PM	Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (GlobeNewswire)
Nov-05-24 04:01PM	Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 (GlobeNewswire)
Oct-30-24 04:01PM	Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.52%
Oct-07-24 01:00AM	Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth (GlobeNewswire)
Sep-30-24 04:01PM	Galapagos receives transparency notification from EcoR1 Capital (GlobeNewswire)
04:01PM	Loading…
Sep-16-24 04:01PM	Galapagos receives transparency notification from EcoR1 Capital (GlobeNewswire)
Sep-03-24 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Aug-23-24 01:00AM	Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (GlobeNewswire)
Aug-20-24 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Aug-01-24 04:01PM	Galapagos reports half-year 2024 financial results and provides second quarter business update (GlobeNewswire) -5.09%
04:01PM	BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology (PR Newswire)
Jun-25-24 05:53AM	GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
Jun-14-24 04:01PM	Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 (GlobeNewswire)
May-30-24 04:01PM	Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications (GlobeNewswire)
04:01PM	Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications (Newsfile)
May-16-24 04:01PM	Galapagos creates new subscription right plans (GlobeNewswire)
May-15-24 04:01PM	Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S. (GlobeNewswire)
May-06-24 10:47AM	Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 04:01PM	Galapagos reports first quarter 2024 financial results (GlobeNewswire)
Apr-30-24 04:01PM	Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024 (GlobeNewswire)
Apr-24-24 09:35AM	Down -9.97% in 4 Weeks, Here's Why You Should You Buy the Dip in Galapagos (GLPG) (Zacks)
Apr-04-24 04:01PM	Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 (GlobeNewswire)
Apr-03-24 09:35AM	After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG) (Zacks)
Mar-28-24 04:01PM	Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings (GlobeNewswire)
Mar-26-24 04:01PM	Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board (GlobeNewswire)
Mar-18-24 09:35AM	Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround (Zacks)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-24-24 08:30AM	Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 04:01PM	Galapagos announces full year 2023 results and outlook for 2024 (GlobeNewswire) -8.28%
04:01PM	Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline (GlobeNewswire)
Feb-15-24 04:01PM	Galapagos presents at EBMT-EHA annual meeting 2024 (GlobeNewswire)
Feb-05-24 07:00AM	NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer (GlobeNewswire)
Jan-31-24 04:01PM	Galapagos completes transaction to transfer Jyseleca business to Alfasigma (GlobeNewswire)
Jan-04-24 04:01PM	Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S. (GlobeNewswire)
Jan-03-24 04:01PM	Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology (GlobeNewswire)
04:01PM	BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets (PR Newswire)
Jan-02-24 01:00AM	Galapagos signs agreement to transfer Jyseleca business to Alfasigma (GlobeNewswire)
Dec-19-23 04:01PM	Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301 (GlobeNewswire)
Dec-09-23 12:00PM	Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 (GlobeNewswire)
Dec-07-23 04:01PM	Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023 (GlobeNewswire)
Nov-06-23 10:32AM	Galapagos NV (NASDAQ:GLPG) Q3 2023 Earnings Call Transcript (Insider Monkey)
07:45AM	Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care (PR Newswire)
Nov-02-23 04:01PM	Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023 (GlobeNewswire) +7.33%
Oct-30-23 04:01PM	Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma (GlobeNewswire)
Sep-19-23 04:01PM	Galapagos appoints Simon Sturge to its Board of Directors (GlobeNewswire)
Aug-28-23 04:01PM	Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus (GlobeNewswire)
Aug-03-23 04:01PM	Galapagos announces first half-year 2023 financial results (GlobeNewswire)
Jun-15-23 04:01PM	Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer (GlobeNewswire)
Jun-12-23 04:01PM	Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board (GlobeNewswire)
Jun-05-23 04:01PM	Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress (GlobeNewswire)
May-23-23 04:01PM	Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis (GlobeNewswire)
May-22-23 04:01PM	Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023 (GlobeNewswire)
May-05-23 04:01PM	Galapagos creates new subscription right plans (GlobeNewswire) +5.90%
May-04-23 04:01PM	Galapagos announces first quarter 2023 financial results (GlobeNewswire)
May-02-23 04:01PM	Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer (GlobeNewswire)
Apr-26-23 04:01PM	Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis (GlobeNewswire)
Apr-25-23 04:01PM	Galapagos shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders meeting (GlobeNewswire)
Mar-30-23 04:30PM	Galapagos and NovAliX enter into an integrated drug discovery collaboration (GlobeNewswire)
Mar-23-23 04:01PM	Galapagos publishes 2022 annual report and announces Annual Shareholders Meeting (GlobeNewswire)
Mar-20-23 04:01PM	Galapagos increases share capital through subscription right exercises (GlobeNewswire)
Feb-27-23 04:01PM	Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023 (GlobeNewswire)
Feb-23-23 04:01PM	Galapagos announces full year 2022 results and outlook for 2023 (GlobeNewswire)
Feb-09-23 04:01PM	Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL (GlobeNewswire) -7.34%
Feb-08-23 04:01PM	Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohns disease (GlobeNewswire)
Jan-10-23 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Jan-03-23 04:01PM	Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-22 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Dec-22-22 04:01PM	Galapagos announces changes to Executive Committee (GlobeNewswire)
Dec-16-22 09:55AM	Does Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect? (Zacks)
Dec-13-22 01:00AM	Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care (GlobeNewswire)
Dec-08-22 09:35AM	Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround (Zacks)
Nov-11-22 07:15AM	Galapagos announces CHMP adoption of PRACs recommendation for Jyseleca® following extensive safety review of all JAK inhibitors (GlobeNewswire)
Nov-08-22 04:01PM	Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022 (GlobeNewswire)
Nov-04-22 04:01PM	Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022 (GlobeNewswire) -5.52%
Nov-03-22 04:01PM	Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results (GlobeNewswire)

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GLPG

Galapagos NV ADR

Upgrade your FINVIZ experience